 |
|
|
|
|
Washington Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2022 replacing WashingtonLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Covance Drug Development
| | | | | Phone: | (425) 979-5000 | | Fax: | (425) 979-5001 | | Year Established: | 1997 | | Employees: | 319 | | Ticker: | LH | | Exchange: | NYSE | | Main Contact: | John Ratliff, CEO | | | | Other Contacts: | Jonathan Zung, Group President, Clinical Development
Herman E. Scholtz, MD, VP & GM, Early Clinical Services
Jonathan Koch, Group President, R&D Laboratories
Chris Gegelys, General Counsel
John Gransee, CFO
Honggang Bi, GM, China
Steven Anderson, CSO
Dimitris K. Agrafiotis, PhD, FRSC, Chief Data Officer
| | | | Company Description | | Covance (formerly Merck/Rosetta) is one of the world's largest and most comprehensive drug development services companies, with annual revenues greater than $2 billion, global operations in more than 30 countries, and more than 11,000 employees worldwide.
Covance offers development services such as safety assessment, clinical pharmacology, consulting, to late-stage development services that include clinical trial management, central laboratory testing, central diagnostics, and commercializationt.
On Feb. 19, 2015, LabCorp® announced the completion of its acquisition of Covance. At closing, the purchase consideration was valued at $107.19 per Covance share, consisting of $75.76 in cash and 0.2686 LabCorp shares for each Covance share, or an equity value of $6.2 billion and an enterprise value of $5.7 billion. | |
|
|
|
|
|
|
|
